期刊文献+

组织胺人免疫球蛋白联合糖皮质激素冲击疗法治疗原发免疫性血小板减少症临床评价

Clinical Evaluation of Histamine Human Immunoglobulin Combined with Glucocorticoid Shock Therapy in the Treatment of Primary Immune Thrombocytopenia
下载PDF
导出
摘要 目的探讨组织胺人免疫球蛋白联合糖皮质激素冲击疗法治疗原发免疫性血小板减少症的临床疗效。方法选取医院2017年6月至2022年6月收治的原发免疫性血小板减少症患者50例,按随机双盲法分为对照组和观察组,各25例。两组患者均在常规治疗基础上予糖皮质激素冲击疗法,观察组患者加用组织胺人免疫球蛋白静脉滴注。两组均治疗2周。结果观察组总有效率为96.00%,明显高于对照组的76.00%(P<0.05);治疗后第3,5,7天,观察组血小板计数均明显高于对照组(P<0.05);观察组血小板计数恢复正常时间、出血停止时间、住院时间均明显短于对照组(P<0.05);观察组不良反应发生率为12.00%,明显低于对照组的40.00%(P<0.05)。结论组织胺人免疫球蛋白联合糖皮质激素冲击疗法治疗原发免疫性血小板减少症,可加快血小板计数恢复速度,及时控制出血症状,且药物对机体的伤害小,患者康复更快。 Objective To explore the clinical efficacy of histamine human immunoglobulin combined with glucocorticoid shock therapy in the treatment of primary immune thrombocytopenia.Methods Fifty patients with primary immune thrombocytopenia admitted to the hospital from June 2017 to June 2022 were randomly divided into the control group and the observation group by the double-blind method,with 25 cases in each group.Both groups received glucocorticoid shock therapy on the basis of routine treatment,on this basis,the observation group received intravenous infusion of histamine human immunoglobulin.Both groups were treated for 2 weeks.Results The total effective rate in the observation group was 96.00%,which was significantly higher than 76.00%in the control group(P<0.05).On the 3rd,5th,and 7th days after treatment,the platelet count in the observation group was significantly higher than that in the control group(P<0.05).The time for platelet count to return to normal,bleeding cessation time,and hospital stay in the observation group was significantly shorter than that in the control group(P<0.05).The incidence of adverse reactions in the observation group was 12.00%,which was significantly lower than 40.00%in the control group(P<0.05).Conclusion Histamine human immunoglobulin combined with glucocorticoid shock therapy in the treatment of primary immune thrombocytopenia can accelerate the recovery of platelet count,timely control bleeding symptoms,minimize the harm of drugs to the body,and promote patients recovery quickly.
作者 段云茹 DUAN Yunru(The Second People's Hospital of Linfen City,Linfen,Shanxi,China 041000)
出处 《中国药业》 CAS 2023年第S02期76-79,共4页 China Pharmaceuticals
关键词 原发免疫性血小板减少症 组织胺人免疫球蛋白 糖皮质激素冲击疗法 血小板计数 出血 临床疗效 primary immune thrombocytopenia histamine human immunoglobulin glucocorticoid shock therapy platelet count bleeding clinical efficacy
  • 相关文献

参考文献11

二级参考文献86

共引文献37

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部